Cancer Research and Treatment

Original Articles

Lung and Thoracic cancer

Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study: Dong-Yun Kim, In Gyu Hwang, Sun Mi Kim, Dae Ryong Kang, Tae-Hwa Go, Se Hwa Hong, Shin Young Park, Hyunho Lee, Jin Hwa Choi; Cancer Res Treat. 2025;57(4):1030-1039. Published online February 6, 2025; DOI: https://doi.org/10.4143/crt.2024.554

Abstract PDF Supplementary Material PubReader ePub: Purpose
Antipsychotic drugs (APDs) can be used to relieve psychological symptoms in patients with cancer. We investigated the nationwide use of APDs during concurrent chemoradiotherapy (CCRT) for patients with lung cancer and its association with overall survival (OS).
Materials and Methods
The National Health Service database was used in this retrospective cohort study. Patients diagnosed with lung cancer between 2010 and 2020 who received cisplatin-based CCRT were included. The APDs included in the analysis were aripiprazole, quetiapine, olanzapine, risperidone, haloperidol, and chlorpromazine, and the APD prescription details included prescription time, dosage, and duration.
Results
Among the 23,099 patients with lung cancer treated with CCRT, 2,662 (11.5%) took APDs concurrently. Quetiapine (47.3%) and chlorpromazine (36.6%) were the frequently prescribed APDs. In the univariate analysis, patients prescribed APDs during CCRT had a significantly worse OS than those who did not take APDs. The 2-year OS rates for APD (+) and APD (–) patients were 20.4% and 36.4%, respectively (p < 0.001). Multivariable analyses revealed that APD prescription, male, age > 80 years, and comorbidities, such as hypertension, myocardial infarction, and depressive disorder, significantly influenced OS. In patients who used APDs during CCRT, APD prescription timing (pre-CCRT vs. during CCRT), dosage (low vs. high) and duration (within 6 months vs. over 6 months) had no significant difference.
Conclusion
Overall, 11.5% of patients with lung cancer used APDs during CCRT. Patients who used APDs during CCRT had poorer survival than those who did not. Further studies are required to elucidate the effects of APDs on patients with cancer.

3,999 View
122 Download

Breast cancer

Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer: Kyung-Hwak Yoon, Yeshong Park, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Se Hyun Kim, Koung Jin Suh, Sun Mi Kim, Mijung Jang, Bo La Yun, So Yeon Park, Hee-Chul Shin; Cancer Res Treat. 2022;54(4):1081-1090. Published online November 17, 2021; DOI: https://doi.org/10.4143/crt.2021.890

Abstract PDF PubReader ePub

Purpose
Estrogen receptor (ER) expression in breast cancer plays an essential role in carcinogenesis and disease progression. Recently, tumors with low level (1%-10%) of ER expression have been separately defined as ER low positive (ER^low). It is suggested that ER^low tumors might be morphologically and behaviorally different from tumors with high ER expression (ERhigh).
Materials and Methods
Retrospective analysis of a prospective cohort database was performed. Patients who underwent curative surgery for early breast cancer and had available medical records were included for analysis. Difference in clinicopathological characteristics, endocrine responsiveness and five-year recurrence-free survival was evaluated between different ER subgroups (ERhigh, ER^low, and ER-negative [ER–]).
Results
A total of 2,162 breast cancer patients were included in the analysis, Tis and T1 stage. Among them, 1,654 (76.5%) were ERhigh, 54 (2.5%) were ER^low, and 454 (21.0%) were ER^- patients. ER^low cases were associated with smaller size, higher histologic grade, positive human epidermal growth factor receptor 2, negative progesterone receptor, and higher Ki-67 expression. Recurrence rate was highest in ER– tumors and was inversely proportional to ER expression. Recurrence-free survival was not affected by hormonal therapy in the ER^low group (p=0.418).
Conclusion
ER^low breast cancer showed distinct clinicopathological features. ER^low tumors seemed to have higher recurrence rates compared to ERhigh tumors, and they showed no significant benefit from hormonal therapy. Future large scale prospective studies are necessary to validate the treatment options for ER^low breast cancer.

Citations

Citations to this article as recorded by

CanAssist Breast Provides Additional Insightful Prognostic Information in Retrospective, Pooled Secondary Analysis in Clinically Low/ High-Risk Patients With HR+/HER2- EBC
Tejal Deepak Durgekar, Susmita Ghosh, Badada Ananthamurthy Savitha, Payal Shrivastava, Naveen Krishnamoorthy, Manvi Sunder, Deepti KS, Manjiri Bakre
Clinical Breast Cancer.2026; 26(2): 216. CrossRef
The Role of Estrogen Receptor–Targeted PET with 16α-18F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis
Jennifer M. Specht, Jasper J.L. van Geel, Shaoli Song, Cheng Liu, Daniel S. Hippe, Nicholas A. DiGregorio, Christine J. Brand, Hannah M. Linden
Journal of Nuclear Medicine.2026; 67(1): 36. CrossRef
Phytochemicals in breast cancer therapy: Decoding molecular pathways and pioneering therapeutic strategies
Putri cahaya Situmorang, Denny Satria, Syafruddin Ilyas, Kaniwa Berliani, Nursahara Pasaribu, Nik Mohd Afizan Nik Abd Rahman, Alexander Patera Nugraha
Phytomedicine Plus.2026; 6(1): 100935. CrossRef
Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression
Sihua Liu, Beidi Du, Mengmeng Zhang, Duanyang Zhai, Xutu Zhao, Nan Shao, Xiaying Kuang, Yunjian Zhang, Yawei Shi, Liang Yu, Ying Lin
Breast Cancer Research and Treatment.2026;[Epub] CrossRef
Prediction of recurrence-free survival in patients with invasive ductal carcinoma of the breast on the basis of clinicopathological, conventional ultrasound and contrast-enhanced ultrasound imaging characteristics
Y. Kuang, Y. Zheng, G. Li, Y. Du, C. Jia, T. Wu, X. Diao, R. Wu
Clinical Radiology.2026; 96: 107256. CrossRef
Distribution and molecular drivers of the 21-gene recurrence score in early breast cancer with low, intermediate, and high estrogen receptor expression
Shuai Li, Jiahui Huang, Yifei Zhu, Jin Hong, Siji Zhu, Weiqi Gao, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen, Jiayi Wu
Frontiers in Immunology.2026;[Epub] CrossRef
CYP2D6 Genotyping for Optimization of Tamoxifen Therapy in Indonesian Women with ER+ Breast Cancer
Baitha Palanggatan Maggadani, Kathleen Irena Junusmin, Fatma Aldila, Jessica Audrienna, Bijak Rabbani, Yusuf Maulana, Sabrina Gabriel Tanu, Gabriella Gabriella, Margareta Amelia, Faustina Audrey Agatha, Marco Wijaya, Stevany Tiurma Sormin, Caroline Mahend
Journal of Personalized Medicine.2025; 15(3): 93. CrossRef
Prognosis, clinicopathological characteristics, and treatment patterns of patients with ER-intermediate-positive breast cancer undergoing long-term follow-up
N. Matsumoto, Y. Wanifuchi-Endo, T. Fujita, T. Asano, M. Terada, K. Nozawa, M. Mori, A. Isogai, Y. Niwa, H. Kato, M. Komura, T. Toyama
ESMO Open.2025; 10(4): 104508. CrossRef
Breast tumors with intermediate ER expression differ biologically from ER-low tumors and exhibit a more favorable prognosis
Yuko Ueki, Yoshiya Horimoto, Kazuharu Harada, Yumiko Ushiyama, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Tsuyoshi Saito, Takahiko Kawate, Takashi Ishikawa, Junichiro Watanabe, Goro Kutomi
Breast Cancer.2025; 32(6): 1255. CrossRef
ER-positive and BRCA2-mutated breast cancer: a literature review
Pu-Chun Li, Yi-Fan Zhu, Wen-Ming Cao, Bei Li
European Journal of Medical Research.2024;[Epub] CrossRef
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy
Nina Eissler, Renske Altena, Ali Alhuseinalkhudhur, Olga Bragina, Joachim Feldwisch, Guido Wuerth, Annika Loftenius, Nikolai Brun, Rimma Axelsson, Vladimir Tolmachev, Jens Sörensen, Fredrik Y. Frejd
Biomedicines.2024; 12(5): 1088. CrossRef
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
Haizhu Chen, Xiujuan Gui, Ziwei Zhou, Fengxi Su, Chang Gong, Shunrong Li, Wei Wu, Nanyan Rao, Qiang Liu, Herui Yao
The Breast.2024; 75: 103733. CrossRef
HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis
Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan, Qiao-Yan Zhu, Yu-Yang Liao, Xiao-Wen Ding, Lin-Feng Zheng, Wen-Ming Cao
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?
Merve Keskinkilic, Huseyin Salih Semiz, Tugba Yavuzsen, Ilhan Oztop
Frontiers in Oncology.2024;[Epub] CrossRef
Rat Models of Hormone Receptor-Positive Breast Cancer
Raquel Nicotra, Catrin Lutz, Hendrik A. Messal, Jos Jonkers
Journal of Mammary Gland Biology and Neoplasia.2024;[Epub] CrossRef
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
Davide Massa, Claudio Vernieri, Lorenzo Nicolè, Carmen Criscitiello, Florence Boissière-Michot, Séverine Guiu, Angélique Bobrie, Gaia Griguolo, Federica Miglietta, Andrea Vingiani, Riccardo Lobefaro, Beatrice Taurelli Salimbeni, Claudia Pinato, Francesca
JNCI: Journal of the National Cancer Institute.2024; 116(12): 1914. CrossRef
Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis
Hongbo Huang, Tingting Wei, Aijie Zhang, Heng Zhang, Lingquan Kong, Yunhai Li, Fan Li
Scientific Reports.2024;[Epub] CrossRef
The “lows”: Update on ER-low and HER2-low breast cancer
Nicola Fusco, Giuseppe Viale
The Breast.2024; 78: 103831. CrossRef
Estrogenized HSA induced high-affinity autoantibodies in breast cancer - Novel biomarker for early detection
Subuhi Sherwani, Mohd Wajid Ali Khan, Wahid Ali Khan, Saravanan Rajendrasozhan, Khalid Al-Motair, Hamda Khan, Saheem Ahmad
Frontiers in Oncology.2024;[Epub] CrossRef
Transcription factors and hormone receptors: Sex‑specific targets for cancer therapy (Review)
Juyeon Kim, Hyobin Bang, Cheyun Seong, Eun-Sook Kim, Sun Kim
Oncology Letters.2024;[Epub] CrossRef
Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment
Anwar Shams
Discover Oncology.2024;[Epub] CrossRef
Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study
Ogur Karhan, Serdar İleri, Zuhat Urakçı, Hayati Arvas, Delyadıl Karakaş Kılıç, Yasin Sezgin, Berrak Merit Erçek, Sezai Tunç
Oncology.2024; 103(6): 498. CrossRef
Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL
Xujuan Zhang, Pengxiang Zhao, Mingshen Ma, Hao Wu, Rui Liu, Ziyi Liu, Zisong Cai, Mengyu Liu, Fei Xie, Xuemei Ma
Frontiers in Medicine.2023;[Epub] CrossRef
Assessment of breast cytoarchitecture and its associated axillary lymph node status under normal and pathological conditions in Egyptian women
Omnia Mansour, Amani Kazem, Abeer El Wakil
Tissue and Cell.2023; 85: 102244. CrossRef
Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives
Christina Panagiotis Malainou, Nikolina Stachika, Aikaterini Konstantina Damianou, Aristotelis Anastopoulos, Ioanna Ploumaki, Efthymios Triantafyllou, Konstantinos Drougkas, Georgia Gomatou, Elias Kotteas
Current Oncology.2023; 30(11): 9734. CrossRef

11,485 View
264 Download
26 Web of Science
25 Crossref

First
Prev
Page of 1
Next
Last

Search